Complementary use of mpMRI and genomic testing in prostate cancer

Around the Practice | <b>Around the Practice June 23, 2021: Genomic and Genetic Testing in Prostate Cancer</b>

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.

Related Content:

Around the Practice June 23, 2021: Genomic and Genetic Testing in Prostate CancerAround the PracticeGenomic Testing
Factors linked to increased likelihood of germline mutations in renal cell carcinoma
Dr. Alexis Rompré-Brodeur on germline testing in renal cell carcinoma
Novel urine-based liquid biopsy launched in US prostate cancer market